BACKGROUND AND AIMS: HIV has reached high prevalence in many non-injecting drug user (NIDU) populations. The aims of this study were to (1) examine the trend in HIV prevalence among non-injecting cocaine and heroin NIDUs in New York City, (2) identify factors potentially associated with the trend and (3) estimate HIV incidence among NIDUs. DESIGN: Serial-cross sectional surveys of people entering drug treatment programs. People were permitted to participate only once per year, but could participate in multiple years. SETTING: Mount Sinai Beth Israel drug treatment programs in New York City, USA. PARTICIPANTS: We recruited 3298 non-injecting cocaine and heroin users from 2005 to 2014. Participants were 78.7% male, 6.1% white, 25.7% Hispanic and 65.8% African American. Smoking crack cocaine was the most common non-injecting drug practice. MEASURES: Trend tests were used to examine HIV prevalence, demographics, drug use, sexual behavior and use of antiretroviral treatment (ART) by calendar year; χ2 and multivariable logistic regression were used to compare 2005-10 versus 2011-14. FINDINGS: HIV prevalence declined approximately 1% per year (P < 0.001), with a decline from 16% in 2005-10 to 8% in 2011-14 (P < 0.001). The percentages of participants smoking crack and having multiple sexual partners declined and the percentage of HIV-positive people on ART increased. HIV incidence among repeat participants was 1.2 per 1000 person-years (95% confidence interval = 0.03/1000-7/1000). CONCLUSIONS: HIV prevalence has declined and a high percentage of HIV-positive non-injecting drug users (NIDUs) are receiving antiretroviral treatment, suggesting an end to the HIV epidemic among NIDUs in New York City. These results can be considered a proof of concept that it is possible to control non-injecting drug use related sexual transmission HIV epidemics.
BACKGROUND AND AIMS: HIV has reached high prevalence in many non-injecting drug user (NIDU) populations. The aims of this study were to (1) examine the trend in HIV prevalence among non-injecting cocaine and heroin NIDUs in New York City, (2) identify factors potentially associated with the trend and (3) estimate HIV incidence among NIDUs. DESIGN: Serial-cross sectional surveys of people entering drug treatment programs. People were permitted to participate only once per year, but could participate in multiple years. SETTING: Mount Sinai Beth Israel drug treatment programs in New York City, USA. PARTICIPANTS: We recruited 3298 non-injecting cocaine and heroin users from 2005 to 2014. Participants were 78.7% male, 6.1% white, 25.7% Hispanic and 65.8% African American. Smoking crack cocaine was the most common non-injecting drug practice. MEASURES: Trend tests were used to examine HIV prevalence, demographics, drug use, sexual behavior and use of antiretroviral treatment (ART) by calendar year; χ2 and multivariable logistic regression were used to compare 2005-10 versus 2011-14. FINDINGS: HIV prevalence declined approximately 1% per year (P < 0.001), with a decline from 16% in 2005-10 to 8% in 2011-14 (P < 0.001). The percentages of participants smoking crack and having multiple sexual partners declined and the percentage of HIV-positive people on ART increased. HIV incidence among repeat participants was 1.2 per 1000 person-years (95% confidence interval = 0.03/1000-7/1000). CONCLUSIONS: HIV prevalence has declined and a high percentage of HIV-positive non-injecting drug users (NIDUs) are receiving antiretroviral treatment, suggesting an end to the HIV epidemic among NIDUs in New York City. These results can be considered a proof of concept that it is possible to control non-injecting drug use related sexual transmission HIV epidemics.
Authors: D C Des Jarlais; T Perlis; S R Friedman; S Deren; T Chapman; J L Sotheran; S Tortu; M Beardsley; D Paone; L V Torian; S T Beatrice; E DeBernardo; E Monterroso; M Marmor Journal: Am J Public Health Date: 1998-12 Impact factor: 9.308
Authors: Charles H Hinkin; Terry R Barclay; Steven A Castellon; Andrew J Levine; Ramani S Durvasula; Sarah D Marion; Hector F Myers; Douglas Longshore Journal: AIDS Behav Date: 2007-03
Authors: D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky Journal: JAMA Date: 1989-02-17 Impact factor: 56.272
Authors: Don C Des Jarlais; Kamyar Arasteh; Theresa Perlis; Holly Hagan; Abu Abdul-Quader; Douglas D Heckathorn; Courtney McKnight; Heidi Bramson; Chris Nemeth; Lucia V Torian; Samuel R Friedman Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Louisa Degenhardt; Bradley Mathers; Mauro Guarinieri; Samiran Panda; Benjamin Phillips; Steffanie A Strathdee; Mark Tyndall; Lucas Wiessing; Alex Wodak; John Howard Journal: Int J Drug Policy Date: 2010-02-01
Authors: Brandon D L Marshall; Evan Wood; Jean A Shoveller; Thomas L Patterson; Julio S G Montaner; Thomas Kerr Journal: BMC Public Health Date: 2011-01-07 Impact factor: 3.295
Authors: Hannah K Knudsen; Jennifer Cook; Michelle R Lofwall; Sharon L Walsh; Jamie L Studts; Jennifer R Havens Journal: Subst Abuse Treat Prev Policy Date: 2017-08-16